Intervention

GnRH agonist

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions11

Lead sponsors shown6

Clinical trials

6 shown

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNCT07596212 · 2026-09-01

NOT_YET_RECRUITING

Cardiovascular Events in GnRH Agonist vs. AntagonistNCT04182594 · 2020-01-17

Intramuscular Mechanisms of Androgen Deprivation-related SarcopeniaNCT03867357 · 2018-12-07

Females, Aging, Metabolism, and ExerciseNCT01712230 · 2012-10-01

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate CancerNCT01546987 · 2012-05-01

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone MetastasesNCT00079001 · 2004-01-01

Common conditions

Prostate Cancer3 Androgen Deprivation Therapy1 Breast Cancer1 Cardiac Event1 Early-stage Breast Cancer1 Hormone Receptor Positive Breast Carcinoma1 Hormone Sensitive Prostate Cancer1 Hypoactive Sexual Desire Disorder1 Metastatic Cancer1 Metastatic Prostate Cancer1 Obesity1

Leading sponsors

Alliance for Clinical Trials in Oncology1 Rabin Medical Center1 Radiation Therapy Oncology Group1 Seattle Institute for Biomedical and Clinical Research1 University of Colorado, Denver1 University of Illinois at Chicago1

Trial status mix

COMPLETED4

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE22

PHASE32

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.